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Summary
Recent studies have shown that the inhibition of casein kinase 2 (CK2) sen-
sitizes many cancer cells to Fas ligand- and tumour necrosis factor-related
apoptosis-inducing ligand (TRAIL)-induced apoptosis. However, it has not
been demonstrated directly whether CK2 inhibition can also enhance the
cytotoxicity of natural killer (NK) cells, which actually use the death ligands to
kill cancer cells in vivo. To address whether NK cell-mediated cancer cell death
is affected by the inhibition of CK2,we first checked whether the death ligand-
induced apoptosis of hepatocellular carcinoma cells (HCCs) and HeLa were
affected by CK2 inhibition.We then investigated the effect of CK2 inhibition
on NK cytotoxicity against HCCs and HeLa cells and its mechanistic features.
Inhibition of CK2 by emodin increased the apoptotic cell death of HepG2,
Hep3B and HeLa when the cancer cell lines were treated with a soluble form
of recombinant TRAIL or an agonistic antibody of Fas. This phenomenon
appeared to be correlated with the expression level of death receptors on the
cancer cell surface. More interestingly, the inhibition of CK2 also greatly
increased theNK cell-mediated cancer cell killing. TheNK cytotoxicity against
the cancer cells increased about twofold when the target cells were pretreated
with a specific CK2 inhibitor, emodin or 4,5,6,7-tetrabromobenzotriazole.
Furthermore, the increase of the NK cytotoxicity against cancer cells by CK2
inhibition was granule-independent and mediated possibly by the death
ligands on the NK cell surface. This suggests that CK2 inhibitors could be used
to enhance the cytotoxicity of NK cells and consequently increase host
tumour immunity.
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Introduction
Natural killer (NK) cells are a distinct subset of large granu-
lar lymphocytes, which possess the ability to kill certain
primary tumour cells, tumour cell lines, virus-infected
cells and transplanted allogenic cells. NK cells are able to lyse
target cells spontaneously without the need for specific
antigen recognition or prior sensitization [1,2]. In particular,
NK cells are believed to play important roles in tumour
immunity [3]. It is well known that NK cells kill many leu-
kaemia cells effectively [2,4], and more recent studies have
demonstrated that NK cells can destroy many solid tissue-
derived malignant cells, such as melanoma, breast cancer,
lung cancer, gastric cancer, colon cancer, renal cancer,
ovarian cancer and hepatoma cell lines [5–8].
Two major pathways are involved in the killing mecha-
nism of NK cells, just as in the case of cytotoxic T cells.
One pathway involves a polarized secretion of preformed
perforin and granzymes by NK cell granule exocytosis,
which leads to rapid caspase activation in target cells, as
well as a caspase-independent death pathway [4,9–12].
Perforin can induce necrosis of target cells and granzymes
can induce apoptosis of target cells [9,10,13]. In another
pathway, death receptors on target cells are cross-linked
by NK cells’ death ligands and these interactions trigger a
relatively well-studied apoptotic death pathway [5,6,14,15].
The non-secretory/apoptotic pathway is mediated by
the Fas ligand (FasL)/Fas, tumour necrosis factor
(TNF)/TNF receptor and TNF-related apoptosis-inducing
ligand (TRAIL)/TRAIL receptor interactions, which
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trigger a cell death pathway involving caspase activation
[5,6,8,14–18].
Death ligands expressed on killer cells induce apoptosis of
target cells in vivo, but it is well known that soluble forms of
TRAIL or agonistic anti-Fas antibodies can also induce the
apoptotic cell death of certain cancer cells [19,20]. However,
many cancer cells are resistant to the soluble forms of
TRAIL- and/or FasL-induced apoptosis, although most of
them express death receptors on the surface [21,22]. In par-
ticular, most hepatocellular carcinoma cells (HCCs) are
resistant to death receptor-mediated apoptosis when the cell
surface death receptor is cross-linked in vitro with either
agonistic antibodies or soluble forms of death ligand
proteins [22–28].
Casein kinase 2 (CK2) is a serine/threonine protein kinase
[29,30] which plays a key role in cell cycle control, cellular
differentiation and proliferation [31–33]. CK2 also partici-
pates in the regulation of apoptosis by phosphorylating some
apoptosis-related factors [21,34–36]. Interestingly, CK2 has
been found to be up-regulated in many cancer cells [37–39].
Increased expression of CK2 protects cells from Fas- and
drug-induced apoptosis, suggesting that CK2 may have a
general anti-apoptotic function [36,40]. Recent studies have
shown that the inhibition of CK2 sensitizes many cancer
cells, such as rhabdomyosarcoma, colon carcinoma, breast
cancer, cervical cancer and gastric cancer to FasL- and
TRAIL-induced apoptosis [21,36,41–43]. However, it has not
been demonstrated directly whether CK2 inhibition can also
enhance the cytotoxicity of killer cells, which actually use the
death ligands to kill cancer cells in vivo.
In a previous report, we demonstrated that NK cells can
effectively kill HCCs using the granule-dependent necrotic
pathway and the death ligand-dependent apoptotic pathway
[8]. In this study, we addressed whether NK cell-mediated
cancer cell death is affected by the inhibition of CK2 in target
cells. We first checked whether the death ligand-induced
apoptosis of HCCs and HeLa were affected by CK2
inhibition. Then, we investigated the effect of CK2 inhibition
on NK cytotoxicity against HCCs and HeLa cells and its
mechanistic features.
Materials and methods
Natural killer cell preparation
Natural killer cells were purified from the whole blood of
healthy volunteers by negative selection using the Rosette-
Sep™ NK enrichment antibody cocktail (StemCell Tech-
nologies Inc., Vancouver, Canada), as described previously
[8]. Briefly, 1 ml of whole blood was mixed with 50 ml of
RosetteSep™ NK enrichment cocktail and incubated for
20 min at room temperature. The blood sample was then
diluted with the same volume of phosphate-buffered saline
(PBS; pH 7·4) containing 2% of fetal bovine serum (FBS)
(Gibco BRL, Grand Island, NY, USA). The diluted sample
was layered on the top of Ficoll-Paque (Amersham Pharma-
cia Biotech, Uppsala, Sweden) and centrifuged for 20 min at
room temperature. The NK cell layer was collected and the
enriched NK cells were washed three times with PBS con-
taining 2% FBS. Purified NK cells were >80% CD56+ CD16+/
CD3- (Beckman Coulter, Fullerton, CA, USA) and were
maintained for 2 weeks in RPMI-1640 media containing
10% FBS and 100 units/ml of recombinant interleukin-2
(Endogen, Woburn, MA, USA).
Cell lines and culture
Hepatocellular carcinoma cell lines HepG2 [American Type
Culture Collection (ATCC) HB 8065] and Hep3B (ATCC HB
8064) were used as target cell lines and maintained in modi-
fied Eagle’s medium (MEM) containing 10% FBS (Gibco
BRL). HeLa was also cultured in Dulbecco’s MEM contain-
ing 10% FBS and used as target cells for cytotoxicity assay.
Antibodies and reagents
Anti-Fas antibody (clone CH11), recombinant TRAIL
(rTRAIL), emodin and 4,5,6,7-tetrabrombenzotriazole
(TBB) were purchased from Medical & Biological Laborato-
ries (Nagoya, Japan), Serotec (Oxford, UK) and Calbiochem
(San Diego, CA, USA) respectively. Anti-caspase-3 and anti-
poly ADP-ribose polymerase (PARP) antibodies were pur-
chased from Cell Signalling Technology (Boston, MA, USA).
Flow cytometric analysis
Cell surface receptors and ligands were quantified by flow
cytometric analysis. NK cells and tumour cells were washed
twice with ice-cold PBS containing 0·05% bovine serum
albumin (BSA). Cells were incubated with phycoerythrin-
labelled anti-DR4, anti-DR5, anti-Fas, anti-FasL and anti-
TRAIL antibody (Biolegend, San Diego, CA, USA) for
30 min at 4°C. After two washes with 0·05% BSA–PBS,
cells were analysed using a fluorescence activated cell sorter
(FACScalibur) flow cytometer (BD Bioscience, Franklin
Lakes, NJ, USA).
The JAM test (DNA fragmentation assay)
Natural killer cell-mediated apoptotic target cell death was
measured using a [3H]-thymidine release assay, the JAM test
[44]. For labelling, 2 ¥ 104 cells were incubated with 20 mCi
of [3H]-thymidine (37 MBq/ml; Nen, Boston, MA, USA) for
20 h at 37°C in a 96-well microtitre plate. Cells were then
washed three times with culture media without FBS. NK cells
and [3H]-thymidine-labelled target cells were mixed at the
indicated effector : tarhet (E : T) ratio. After 2 h of incuba-
tion in the presence or absence of the CK2 inhibitor, the cells
and their medium were aspirated onto glass fibre filters (size
90 ¥ 120 mm) using a semi-automated 96-well harvester
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(Tomtec, Hamden, CT, USA). The filters (Wallac Oy, Turku,
Finland) were washed, dried and sealed with melt-on scin-
tillator sheets (Wallac) and radioactivity was measured with
a beta counter (Wallac). rTRAIL- and CH11-induced cancer
cell death was measured similarly using the JAM test. For this
assay, target cells were treated with rTRAIL or CH11 for 6 h
in the presence or absence of the CK2 inhibitors. Percentage
of apoptotic cell death was calculated by the following
formula: % DNA fragmentation = [1 - (experimental value/
control value)] ¥ 100. The control value was determined by
incubating target cells in culture medium alone.
Lactate dehydrogenase assay
Recombinant TRAIL- and CH11-induced cancer cell death
was also assessed by lactate dehydrogenase (LDH) assay
using the CytoTox 96 assay kit (Promega, Madison, WI,
USA). Target cells, 1 ¥ 104, were prepared in a 96-well
microtitre plate and treated as indicated in the figure
legends. For the LDH-positive control, 10 ml of lysis solution
(10¥) were added to all wells to lyse cells, and the target cells
were incubated for 45 min. An aliquot of 50 ml was taken
from each well and transferred to a fresh 96-well flat-
bottomed (enzymetic assay) plate. To each well of the plate,
50 ml of substrate mix was added, and the plate was incu-
bated for 30 min in the dark. After 30 min, 50 ml of stop
solution was added to each well and the absorbance was
recorded at 490 nm within 1 h using an enzyme-linked
immunosorbent assay reader.
51Chromium release assay
Natural killer cell-mediated target cell killing was assessed
using a standard 51Cr release assay, as described previously
[8]. For labelling, 3 ¥ 103 cells were incubated with 10 mCi of
51Chromium (51Cr) (Nen) for 60 min at 37°C in 96-well
microtitre plates, then washed three times with culture
media without 10% FBS. 51Cr-labelled target cells and NK
cells were mixed at the indicated E : T ratio. After 4 h of
co-culture with NK cells, cell-free supernatant was collected
and radioactivity was measured with a gamma counter.
Percentage of specific 51Cr release was calculated by the
following formula:% cytotoxicity = [(experimental 51Cr
release - spontaneous 51Cr release)/(maximum 51Cr release -
spontaneous 51Cr release)] ¥ 100. For control experiments,
target cells were incubated either in culture medium alone to
determine spontaneous release or in a mixture of 2% Triton
X-100 to define maximum 51Cr release. Data are presented as
the mean of at least three independent experiments.
Western blot
Target cells were lysed with a lysis buffer (10 mM Tris-HCL,
pH 7·4 150 mM NaCl, 2 mM ethylenediamine tetraacetic
acid, 1% Triton X-100, 1 mM phenylmethylsulphonyl
fluoride, 15 mg/ml leupeptin, 2 mM NaF, 2 mM NaVO4), and
the lysates were separated on sodium dodecyl sulphide-
polyacrylamide gels. The protein bands were transferred to
polyvinylidene difluoride membranes (Pierce, Rockford, IL,
USA). The membranes were blocked with 5% BSA in PBS
containing 0·1% Tween-20 (PBST) for 2 h, incubated with
proper antibodies for 4 h, and washed with PBST. The mem-
branes were then incubated with peroxidase-conjugated goat
anti-mouse IgG (H + l) for 2 h, and washed with PBST. The
blots were finally visualized by Supersignal WestDico chemi-
luminescent substrate (Pierce).
Fixation of NK cells
For blocking granule release, NK cells were incubated for
20 min with RPMI-1640 containing 0·5% paraformaldehyde
and washed twice with PBS. The concentration of paraform-
aldehyde and the incubation time was minimized to avoid
adverse effects as much as possible.
Results
Casein kinase 2 inhibitor augments rTRAIL-induced
apoptosis of HCCs
In a previous report, we demonstrated that NK cells effec-
tively killed HCCs using the granule-dependent necrotic
pathway and the death ligand-dependent apoptotic pathway
[8]. Interestingly, recent studies have shown that inhibition
of CK2 sensitizes many cancer cells to TRAIL-induced apo-
ptosis [21,36,41–43]. As a first step to investigate the effect of
CK2 inhibition on the NK cytotoxicity against HCCs, we
checked whether the death ligand-induced apoptosis of
HCCs were affected by CK2 inhibition, as it has not yet been
demonstrated. For this purpose, HepG2 and Hep3B cell lines
were treated for 24 h with emodin, a CK2 inhibitor [45], in
the presence and absence of rTRAIL (10 ng/ml). In order to
observe the apoptotic target cell death, the extent of DNA
fragmentation was measured using a [3H]-thymidine release
assay [44]. As shown in Fig. 1a, rTRAIL or emodin alone
induced only limited apoptotic cell death of HepG2 or
Hep3B. However, the HepG2 and Hep3B cells exhibited a
significant amount of DNA fragmentation when the cells
were co-treated with rTRAIL and emodin (Fig. 1a). Similar
phenomena were observed when the target cell death was
measured by LDH assay (Fig. 1b). Emodin or rTRAIL alone
induced only limited cell death of HepG2 and Hep3B, but
co-treatment of rTRAIL with emodin increases significantly
the rTRAIL-induced cell death. Both HepG2 and Hep3B
expressed DR5 (TRAIL receptor 2), but not DR4 (TRAIL
receptor 1) (Fig. 1c). As a result, both HepG2 and Hep3B
cells were sensitive to rTRAIL-induced apoptosis, and was
enhanced in the presence of emodin (Fig. 1a and b).
We next investigated the dose-dependent effects of
rTRAIL and emodin on the apoptosis of HCCs by using the
H.-R. Kim et al.
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JAM test. As shown in Fig. 2a, apoptotic cell death of HepG2
increased gradually as the amount of emodin increased from
2 to 20 mg/ml in the absence of rTRAIL (black bars, left
panel). Furthermore, much greater apoptotic cell death
of HepG2 was observed when the amount of emodin was
varied from 2 to 20 mg/ml in the presence of a fixed amount
of rTRAIL (10 ng/ml; white bars, left panel). The apoptotic
cell death of HepG2 increased only slightly when the amount
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Fig. 1. Effects of casein kinase 2 inhibitor (emodin) on the recombinant tumour necrosis factor-related apoptosis-inducing ligand
(rTRAIL)-induced cancer cell death. (a) rTRAIL-induced apoptotic cell death of hepatocellular carcinoma cells assessed by the JAM test. HepG2
and Hep3B cells were labelled with [3H]-thymidine for 1 day and treated with 10 mg/ml of emodin. After 1 day, 10 ng/ml of rTRAIL was used to
treat the target cells for 6 h, and the radioactivity was measured by a b-counter. (b) rTRAIL-induced target cell death measured by the lactate
dehydrogenase (LDH) assay. Target cells were seeded to 96-well microplates and treated with emodin. After 1 day, rTRAIL was used to treat target
cells for 18 h, and 50 ml aliquots of the media were used for the LDH assay. The data are presented as a mean of at least three independent
experiments (mean standard deviation). (c) DR4 and DR5 expressions on HepG2 and Hep3B were determined by flow cytometry (black line:
isotype control, grey filled area: receptor expression).
Fig. 2. Dose-dependent effect of recombinant
tumour necrosis factor-related apoptosis-
inducing ligand (rTRAIL) and emodin. (a)
HepG2 and (b) Hep3B target cells were used
for the JAM test. Left panels show the dose-
dependent effect of emodin on the rTRAIL-
induced target cell death. rTRAIL at a
concentration of 10 ng/ml was used to induce
apoptotic cell death of target cells. Right panels
show the dose-dependent effect of rTRAIL on
the target cell death in the presence of 10 mg/ml
emodin. The target cells were incubated with
emodin for 1 day and treated with rTRAIL.
After 6 h, the radioactivity of target cells was
detected by a b-counter. The data are presented
as a mean of at least three independent
experiments (mean standard deviation).
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of rTRAIL increased from 5 to 40 ng/ml in the absence of
emodin (black bars, right panel). However, the apoptotic cell
death of HepG2 increased substantially as the amount of
rTRAIL increased in the presence of the fixed amount of
emodin (10 mg/ml; white bars, right panel). Similar dose-
dependent effects of rTRAIL and emodin were observed
when Hep3B cells were treated with emodin or rTRAIL
(Fig. 2b, black bars), and when the cells were co-treated with
rTRAIL and emodin (white bars, Fig. 2b).
Casein kinase 2 inhibition increased the FasL-induced
apoptosis of HCCs
We next checked whether the FasL-induced apoptosis of
HCCs were also affected by CK2 inhibition. For this purpose,
HepG2 and Hep3B cell lines were treated for 24 h with
emodin in the presence or absence of an agonistic mono-
clonal anti-Fas antibody (CH11) [46]. When the amount of
cell death was measured by the JAM test, CH11 or emodin
alone induced only limited apoptotic cell death of HepG2
and Hep3B (Fig. 3a). It is well known that HepG2 cells are
resistant to FasL-induced apoptosis, although it expresses Fas
[22–28]. However, the HepG2 cells exhibited a significant
amount of DNA fragmentation when the cells were
co-treated with CH11 and emodin (Fig. 3a, left panel).
Unlike HepG2 cells, Hep3B cells did not express Fas
(Fig. 3c). Consequently, simultaneous treatment of CH11
and emodin did not induce any significant apoptosis in
Hep3B cells (Fig. 3a, right panel). Similar phenomena were
observed when the target cell death was measured by LDH
assay (Fig. 3b). CH11 or emodin alone induced only a
limited amount of cell death in HepG2 and Hep3B; however,
CH11 and emodin co-treatment increased the CH11-
induced cell death significantly in HepG2 cells, but not in
Hep3B cells.
Effect of CK2 inhibition on death ligand-induced
HeLa cell death
We next investigated the effect of CK2 inhibition on death
ligand-induced cell death of other tumour cells. A cervical
cancer cell line, HeLa, was chosen for this purpose. HeLa cells
strongly expressed Fas and DR5, death receptors for FasL and
TRAIL respectively (Fig. 4a). As expected, CK2 inhibition
appeared to augment the rTRAIL- and CH11-induced apop-
totic cell death of HeLa in the JAM test (Fig. 4b). Interestingly,
we found that HeLa cells were sensitive to emodin treatment.
As shown in Fig. 4a, emodin alone induced more apoptotic
cell death than rTRAIL or CH11 for unknown reason.
Effects of CK2 inhibition on NK cell-mediated
apoptosis
We next investigated the effect of CK2 inhibition on NK
cytotoxicity against three cancer cell lines,HepG2,Hep3B and
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Fig. 3. Effects of casein kinase 2 inhibitor on the CH11-induced target cell death. CH11-induced apoptotic cell death of target cells was assessed by
the JAM test. HepG2 and Hep3B cells were labelled with [3H]-thymidine for 1 day and treated with 10 mg/ml of emodin. After 1 day, 250 ng/ml of
CH11 was used to treat the target cells for 6 h, and the radioactivity was measured by a b-counter. (b) CH11-induced target cell death was
measured by the lactate dehydrogenase (LDH) assay. Target cells were seeded in 96-well microplates and treated with 10 mg/ml of emodin.
After 1 day, 250 ng/ml of CH11 was used to treat target cells for 18 h, and 50 ml aliquots of the media were used for the LDH assay. The data are
presented as a mean of at least three independent experiments (mean standard deviation). (c) Fas expressions on HepG2 and Hep3B were
determined by flow cytometry (black line: isotype control, grey filled area: Fas expression).
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HeLa. In order to observe the apoptotic target cell death
mediated by NK cells, the extent of DNA fragmentation was
measured by the JAM test, a [3H]-thymidine release assay.
When target cells were co-incubated with NK cells for 2 h,
Hep3B and HeLa cells exhibited a significant amount of DNA
fragmentation, whereas HepG2 cells showed a relatively small
amount of DNA fragmentation (Fig. 5a, white bars). When
the target cells were pretreated with emodin and co-incubated
with NK cells, all three cancer cell lines exhibited a greatly
increased amount of apoptotic cell death (grey bars). Emodin
alone induced limited apoptotic cell death only in HepG2 and
Hep3B, but for unknown reasons it induced a significant
apoptotic cell death in HeLa (black bars).
Similar results were obtained when the NK cells and target
cells were co-incubated in the presence of TBB, a more spe-
cific CK2 inhibitor [47]. TBB is one of the most efficient
inhibitors for CK2, along with 2-dimethylamino-4,5,6,7-
tetrabromo-1H-benzimidazole [48]. As shown in Fig. 5b,
when the target cells were pretreated with TBB and
co-incubated with NK cells, all three cancer cell lines exhib-
ited a greatly increased amount of apoptotic cell death (grey
bars) as measured by the JAM test. We next investigated the
effect of TBB on the necrotic target cell death mediated by
NK cells using a 4 h 51Cr release assay. The standard 4 h 51Cr
release assay is known to measure primarily the necrotic cell
death induced by the cytotoxic granules of NK cells [7,8,24].
As shown in Fig. 5c and d, NK cells induced necrotic cell
death when the target cells were co-incubated with NK cells
(white bars). However, treatment of neither emodin nor TBB
increased the NK cytotoxicity against the cancer cell lines
(grey bars). These results indicated that the inhibition of
CK2 of cancer cells augmented the NK cell-mediated apop-
totic killing of target cells.
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Fig. 4. Effects of emodin on the recombinant tumour necrosis
factor-related apoptosis-inducing ligand (rTRAIL)- and
CH11-induced HeLa cell death. (a) Fas, DR4 and DR5 expressions on
HeLa were determined by flow cytometry (black line: isotype control,
grey filled area: receptors expression). (b) JAM test. HeLa cells were
labelled with [3H]-thymidine for 1 day and treated with 10 mg/ml of
emodin. After 1 day, rTRAIL or CH11 was used to treat the target cells
for 6 h. The radioactivity of HeLa cells was measured by a b-counter.
The data are presented as a mean of at least three independent
experiments (mean standard deviation).H17009: rTRAIL or CH11 alone.
Fig. 5. Effects of casein kinase 2 inhibitors on
natural killer (NK) cell-mediated tumour cell
killing. NK cell-induced apoptotic target cell
death was assessed by the JAM test. Target cells
were labelled with [3H]-thymidine for 1 day,
and 10 mg/ml of emodin (a) and 5 mM TBB (b)
were used to treat the target cells. After 1 day,
target cells were co-cultured with NK cells with
an effector : target (E : T) ratio of 3:1 for 2 h.
The radioactivity of target cells was measured
by a b-counter. The NK cytotoxicity against
tumour cells was also determined by 51Cr
release assay. Target cells were incubated with
emodin (c) and TBB (d) for 1 day. Then, the
target cells were labelled with 51Cr and
incubated with NK at an E : T ratio of 3:1 for
4 h. The data are presented as a mean of
at least three independent experiments
(mean standard deviation).
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Casein kinase 2 inhibition increases the NK
cell-mediated cancer killing by a granule-independent
process
In order to investigate whether or not the increase of NK
cytotoxicity against cancer cells by CK2 inhibition is granule-
dependent, NK cells were fixed mildly with 0·5% paraform-
aldehyde and the cytotoxicities against cancer cells in the
presence or absence of CK2 inhibitor were compared. The
mild fixation of NK cells or macrophages eliminates the
granule release without affecting the structure and function
of the cell surface receptors [7,8,49]. As reported previously
[8], the fixed NK cells were almost as effective as the untreated
NK cells in the JAM test against the HepG2, Hep3B and HeLa
cells (Fig. 6, black bars). When the target cells were pretreated
with emodin or TBB and co-incubated with NK cells, all three
cancer cell lines exhibited almost the same amount of apop-
totic cell death as in the cases of the untreated NK cells (Fig. 6,
white bars and grey bars respectively). In order to confirm the
increased apoptotic cell death induced by NK cells in the
presence of TBB, caspase-3 and PARP cleavages were exam-
ined by immunoblotting (Fig. 6b). The Western blot analysis
shown in Fig. 6b indicated that PARP was more cleaved in
TBB-treated HepG2 cells when the cells were co-incubated
with NK cells, although caspase-3 cleavage did not appear to
be significantly changed. These results suggest that the
increase of the NK-mediated apoptotic cancer cell death by
CK2 inhibition is granule-independent and mediated possi-
bly by the death ligands on the NK cell surface.
Discussion
Recent studies have shown that increased expression of
CK2 protects cancer cells from apoptotic cell death and the
inhibition of CK2 sensitizes many cancer cells to death ligand-
induced apoptosis [22,36,40–43]. In this study, we demon-
strated that HCCs and HeLa cells could also be sensitized to
death ligand-induced apoptosis by inhibition of CK2. Inhibi-
tion of CK2 by emodin increased the apoptotic cell death of
HepG2, Hep3B and HeLa when the cancer cell lines were
treated with a soluble form of rTRAIL or an antagonistic
antibody of Fas. This phenomenon appeared to be correlated
with the expression level of death receptors on the cancer cell
surface. More interestingly, inhibition of CK2 also increased
greatly the NK cell-mediated cancer cell killing. The NK
cytotoxicity against the cancer cells increased about twofold
when the target cells were pretreated with a CK2 inhibitor,
emodin or TBB. Furthermore, the increase of the NK cyto-
toxicity against cancer cells by CK2 inhibition was granule-
independent. These results suggest that NK cytotoxicity
against cancer cells could be augmented in vivo, as well as
in vitro, by inhibition of CK2 using a specific CK2 inhibitor.
Unlike normal hepatocytes, most HCCs are resistant to
death receptor-mediated apoptosis when the cell surface
death receptor is cross-linked in vitro with either agonistic
antibodies or soluble forms of death ligand proteins [22–28].
The resistance of HCCs against death receptor-mediated
apoptosis might be an essential step in escaping from host
immune surveillance. Interestingly, however, our data
showed that HCCs can be sensitized to death ligand-induced
apoptosis by inhibiting the CK2 with emodin. CK2 inhibi-
tion by emodin appeared to increase rTRAIL-induced cell
death significantly in HepG2 and Hep3B (Fig. 1), as well
as increase the agonistic monoclonal anti-Fas antibody
(CH11)-induced cell death in HepG2 (Fig. 3). The death
ligand-induced apoptosis was generally proportional to the
dose of the CK2 inhibitor (Fig. 2). Furthermore, death
ligand-induced apoptotic cell death in the presence of
CK2 inhibitor was also correlated with the death receptor
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Fig. 6. Casein kinase 2 inhibition increased the natural killer (NK)
cell-mediated cancer killing by a granule-independent apoptotic
process. The fixed NK activity of target cell lysis was determined by
JAM test. Target cells were labelled with [3H]-thymidine for 1 day and
pretreated with 10 mg/ml of emodin or 5 mM TBB. Primary NK cells
were fixed by 0·5% paraformaldehyde for 20 min and then added to
target cells at an E : T ratio of 3:1. Fixed NK cells and target cells were
co-cultured for 2 h, and the radioactivity of target cells was measured
by a b-counter. The data are presented as a mean of at least three
independent experiments (mean standard deviation). (b)
Immunoblot analysis of caspase3 and poly ADP-ribose polymerase
(PARP) cleavage in the HepG2, Hep3B and HeLa cells. Target cells
treated by 5 mM of TBB for 1 day were co-cultured with NK cells with
E : T ratio of 3:1 for 2 h. The target cells were collected and lysed and
Western blotting was performed with anti-caspase3 and anti-PARP
antibodies.
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expression level on HCCs. These results suggest that CK2
also plays a critical role in the death receptor-mediated apo-
ptosis of HCCs, as in other cancer cells.
It is well known that NK cells effectively kill many leu-
kaemia cells and that the process is mediated primarily by
perforin and granzymes [4,9–11]. Perforin induces the
necrosis of the target cells and granzymes induce the apop-
tosis of the target cells [15–17]. More recent studies showed
that NK cells can also effectively kill many solid tissue-
derived tumour cells and that the non-secretory/apoptotic
pathway plays a more important role when NK cells elimi-
nate solid tumour cells [7,8]. The non-secretory/apoptotic
pathway is mediated by FasL/Fas, TNF/TNF receptor and
TRAIL/TRAIL receptor interactions [5,6,8,14–17], and the
death receptor-mediated apoptotic pathway is also involved
in the cytotoxicity of NK cells against many leukaemia cells
[12,18]. Previously, we showed that NK cells can effectively
destroy HCCs, like other solid tumours, and that the death
receptor-mediated apoptotic pathway is involved in the NK
cell-mediated HCC killing [8]. In this study, we demon-
strated that the inhibition of CK2 by emodin or TBB aug-
ments NK cytotoxicity against HCCs and HeLa cells in the
2 h [3H]-thymidine release assay (Fig. 5a and b), which
measures primarily the extent of apoptotic target cell death
[7,8,24]. Furthermore, we demonstrated that the mildly
fixed NK cells are as effective as untreated NK cells in the
cytotoxicity against target cells pretreated with emodin or
TBB (Fig. 6a). Because the fixed NK cells cannot secrete the
cytotoxic granules, it is highly likely that the increased NK
cytotoxicity against cancer cells pretreated with the CK2
inhibitors might be mediated by interactions between death
ligands on NK surface and death receptors on cancer cell
surface. This is supported further by the fact that the CK2
inhibition of cancer cells did not increase the NK cytotoxic-
ity against these target cells in the 4 h 51Cr-release assay
(Fig. 5c and d), which measures primarily necrotic cell death
mediated by cytotoxic granules [7,8,24].
Like NK cells, cytotoxic T cells kill target cells by using the
secretory cytotoxic granule-mediated pathway and the death
receptor-mediated apoptotic pathway [18]. Because the
death receptor-mediated apoptotic target cell killing mecha-
nism of cytotoxic T cells is exactly the same as that of NK
cells, it is tempting to speculate that the inhibition of CK2
could also enhance cytotoxic T cell-mediated target cell
killing. This suggests that CK2 inhibitors could increase
the host’s innate and adaptive immunity against cancer by
enhancing the cytotoxicity of NK cells and cytotoxic T cells
which are armed with death ligands.
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